Access in-depth articles, white papers and publications discussing strategies for overcoming challenges in the cell and gene therapy industry.
Donor Pool Size Matters for Allogeneic Cell Therapies
Learn more about the registry size needed to identify a sufficient number of donors who meet study eligibility, health authority and medical suitability requirements for even the most common HLA genotypes.
The Historical HLA Learning Curve
Download our resource on why HLA matching matters featuring an expert opinion from Martin Maiers, MS, Vice President of Biomedical Informatics, CIBMTR® (Center for International Blood and Marrow Transplant Research®).
How to Overcome 3 Common Cell Therapy Supply Chain Disruptions
Learn what we've identified as the most common cell therapy supply chain disruptions and steps you can take to mitigate your risk and variability.
5 Considerations to Lower Your Risk When Selecting a Supply Chain Partner
Learn more about considerations to keep in mind when selecting a cell therapy supply chain partner.
Case Study: The Challenge of Multiple Audits and Redundant Training
Learn about the challenges UCLA Health has encountered with the rapid growth in the cell and gene therapy industry, and how adopting standardized processes can help to overcome these challenges.
A Cell Therapy Industry Turning Point
Learn about how quality system audit standardization can increase collection capacity and reduce risk.
Case Study: Cell Collection Standards for Cell Therapies
Learn about our work with the Standards Coordinating Body to standardize common aspects of cell collection protocols and processes and improve cellular starting material quality.
STAT Plus article: A CAR-T bottleneck
Centers that collect patient cells feel crunch from growing demand -- written by Andrew Joseph
Cell & Gene Therapy Insights Interview
Optimizing the Cell Collection Network to Support the Commercialization of Cell and Gene Therapies
White Paper: Exceptions are the Norm
The importance of patient case management to reduce variability in cell therapy supply chains